Form 4: Galectin CEO Joel Lewis Receives Equity Grant

Galectin Therapeutics Inc. CEO Joel Lewis was granted 84,000 stock options and 120,000 restricted stock units, aligning executive incentives with shareholder value.

Summary

• Joel Lewis, President and CEO, Director, and 10% Owner of Galectin Therapeutics Inc. (GALT), acquired derivative securities.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.
• Acquired 84,000 stock options with an exercise price of $3.04, vesting 25% on June 30, 2026, December 31, 2026, June 30, 2027, and December 31, 2027, and expiring on January 16, 2036.
• Acquired 120,000 Restricted Stock Units (RSUs), which vest 100% on the earlier of December 31, 2026, or the signing of a partnership agreement.
• The RSUs, if vested, convert into Common Stock on a one-for-one basis.
• Following these reported transactions, Joel Lewis beneficially owns 65,000 stock options and 100,000 Restricted Stock Units.

Sentiment

Score: 6

Explanation: The grant of equity to the CEO is generally a positive for aligning interests, but the discrepancy in the reported 'beneficially owned following' numbers introduces a minor element of confusion or potential negative interpretation regarding net holdings.

Positives

• The grant of 84,000 stock options and 120,000 Restricted Stock Units to the President and CEO aligns management's long-term interests with shareholder value.
• The RSU vesting condition tied to a 'partnership agreement' suggests a strategic focus on potential collaborations and value-creating events for the company.

Negatives

• The reported 'Number of derivative Securities Beneficially Owned Following Reported Transaction(s)' (65,000 stock options and 100,000 Restricted Stock Units) is less than the 'Number of Derivative Securities Acquired' (84,000 stock options and 120,000 Restricted Stock Units), implying a net reduction in total holdings of these specific derivative types despite the acquisition, which could indicate other unreported dispositions or a complex accounting of beneficial ownership.

Future Outlook

The vesting schedule for Restricted Stock Units is tied to the earlier of December 31, 2026, or the signing of a partnership agreement, indicating a strategic focus on securing future collaborations and potentially accelerating value creation.

Industry Context

Executive equity grants are a standard practice in the biotechnology and pharmaceutical industry to incentivize leadership and align their performance with long-term company growth and shareholder returns, particularly in companies like Galectin Therapeutics that are focused on drug development and strategic partnerships.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of CEO's interests with long-term company performance and shareholder value.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Achievement of vesting conditions for stock options on June 30, 2026, December 31, 2026, June 30, 2027, and December 31, 2027.
• Achievement of vesting conditions for Restricted Stock Units on the earlier of December 31, 2026, or the signing of a partnership agreement.

Key Dates

Keywords

Galectin Therapeutics, GALT, Joel Lewis, Insider Transaction, Form 4, Stock Options, Restricted Stock Units, Equity Grant, Executive Compensation, Rule 10b5-1